Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

20253 citationsJournal Article

Authors

Matthias Augustin · Universität Hamburg

M. Tauber · Inserm

Robert Sidbury · Seattle Children's Hospital

Jonathan I. Silverberg · George Washington University

Kim Papp · University of Toronto

Diamant Thaçi · University of Lübeck

Marjolein de Bruin‐Weller ·

Abstract

NCT03989206: https://clinicaltrials.gov/search?term=NCT03989206; EUDRACT number: 2019-001889-15. Data available upon request: clinical.studies@galderma.com.

Topics & Keywords

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Asthma and respiratory diseases

Publication Details

Published in: Journal of the European Academy of Dermatology and Venereology

DOI: 10.1111/jdv.70080

Field-Weighted Citation Impact: 6.11

Command Palette

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Authors

Abstract

Topics & Keywords

Publication Details